Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MBX 1416

Peptide · developed by MBX Biosciences

Phase 2 Most advanced trial (none active)
MBX Developer
2 Registered trials

What is MBX 1416?

MBX 1416 is an agent given by subcutaneous injection and studied in postbariatric hypoglycemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Peptide
Therapy area
Metabolic
Developer
MBX Biosciences (MBX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
E8L272T7FX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07029412 Phase 2 Postbariatric Hypoglycemia Completed MBX
NCT06036784 Phase 1 Postbariatric Hypoglycemia Completed MBX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Postbariatric Hypoglycemia

More from MBX Biosciences

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MBX page.

Follow MBX, the company behind MBX 1416

See MBX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MBX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.